New Treatments in Atopic Dermatitis
Price: FREE for members and non-members
Session recorded on June 22, 2022
Speaker: Luz Fonacier, MD
Viewers can earn credit by completing the posttest questions.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
- Discuss underlying pathophysiology of atopic dermatitis and targets of treatment
- Discuss use of assessment tools for Identifying patients with moderate to severe atopic dermatitis
- Discuss current and new treatment of moderate to severe AD
There are many new treatment for AD that has been approved since Dec 2021 and allergists have to be familiar with many treatment options for this common and potentially debilitating disease.
All relevant finaicial relationships have been mitigated.
Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Luz Fonacier, MD, FACAAI Speaker
Disclosures: Advisor: Abbie, Lilly; Advisor, Indpendent Contractor: Regeneron; Advisor, Indpendent Contractor, Researcher: Pfizer
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance